|
注册号: Registration number: |
ChiCTR2300069354 |
|
最近更新日期: Date of Last Refreshed on: |
2025-01-26 15:05:57 |
|
注册时间: Date of Registration: |
2023-03-14 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
跨诊断治疗统一方案(UP-A)对青少年情绪障碍干预的有效性研究 |
|
Public title: |
A Randomized Controlled Trial of the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Adolescents in China |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
跨诊断治疗统一方案(UP-A)对青少年情绪障碍干预的有效性研究 |
|
Scientific title: |
A Randomized Controlled Trial of the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Adolescents in China |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘雪滢 |
研究负责人: |
钱秋谨 |
|
Applicant: |
Liu Xueying |
Study leader: |
Qian Qiujin |
|
申请注册联系人电话: Applicant telephone: |
+86 188 2623 4758 |
研究负责人电话:
Study leader's |
+86 10 6272 3701 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
liuxueying1995@hotmail.com |
研究负责人电子邮件: Study leader's E-mail: |
qianqiujin@bjmu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市海淀区花园北路51号 |
研究负责人通讯地址: |
北京市海淀区花园北路51号 |
|
Applicant address: |
51 Huayuan Road North, Haidian District, Beijing |
Study leader's address: |
51 Huayuan Road North, Haidian District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
北京大学第六医院 |
||
|
Applicant's institution: |
Peking University Sixth Hospital |
||
|
研究负责人所在单位: |
北京大学第六医院 |
||
|
Affiliation of the Leader: |
Peking University Sixth Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2022)伦审第(71)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
北京大学第六医院(精神卫生研究所)医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the Sixth Hospital of Peking University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-12-06 00:00:00 | ||
|
伦理委员会联系人: |
徐文静 |
||
|
Contact Name of the ethic committee: |
Xu Wenjing |
||
|
伦理委员会联系地址: |
北京市海淀区花园北路51号 |
||
|
Contact Address of the ethic committee: |
51 Huayuan Road North, Haidian District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 8207 7885 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
北京大学第六医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Peking University Sixth Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市海淀区花园北路51号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
51 Huayuan Road North, Haidian District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
北京市科技计划课题“首都临床特色诊疗技术研究及转化应用”专项(课题编号:Z221100007422048) |
||||||||||||||||||||||
|
Source(s) of funding: |
Beijing Municipal Science & Technology Commission (Z221100007422048) |
||||||||||||||||||||||
|
研究疾病: |
青少年情绪障碍 |
||||||||||||||||||||||
|
Target disease: |
Emotional Disorders in Adolescents |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
针对我国青少年情绪障碍患者开展团体跨诊断治疗,研究 UP-A对青少年情绪障碍患者的情绪症状、情绪调节、认知模式、执行功能、心理韧性、生活质量及社会功能及家庭功能的改善情况。 |
||||||||||||||||||||||
|
Objectives of Study: |
To conduct a group transdiagnostic treatment in China for adolescents with emotional disorders to study the improvement of UP-A on emotional symptoms, emotion regulation, cognitive patterns, executive function, resilience, quality of life, social and family functioning. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.双相障碍、精神病性障碍、脑器质性疾病、孤独症谱系障碍、精神发育迟滞、物质依赖患者; 2.存在强烈的自杀观念者; 3.接受过系统的认知行为治疗; 4.视听力障碍。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with bipolar disorder, psychotic disorders, brain organic disorder, autism spectrum disorder, mental retardation or substance abuse; 2. High risk of suicide; 3. Have received systematic cognitive behavior therapy previously; 4. Vision or hearing impairment. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-03-15 00:00:00至 To 2025-09-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-03-15 00:00:00 至 To 2025-09-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
研究按照患者的入组顺序由独立的研究人员对患者进行编号,使用SPSS V.25.0软件产生随机化数字,生成对应的分组情况,将患者随机分为UP-A联合常规门诊治疗组(治疗组)和常规门诊治疗组(对照组),之后统计人员将产生的随机分配方案密封保存。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The process of randomization will be performed by an independent researcher who will not be involved in the other study procedures. SPSS V.25.0 will be used to generate random numbers and corresponding groupings, the sequences will be stored in a password-protected data management system. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
对临床评估人员、测查人员设盲 |
|
Blinding: |
Blind clinical evaluators and examiners. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
No |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
研究中采用电子数据采集的方式进行问卷采集,在资料收集一周内将电子问卷纳入数据库。临床访谈及执行功能评估等纸质版资料将采用Epidata录入和管理,在原始资料收集一周内录入数据库,数据不完整或有疑问需及时补充核实。建立受试者资料档案进行临床档案管理,所有档案按编号、类别分装入资料盒后,保存在有锁的档案柜中,仅供研究人员查阅。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic data collection was used to collect questionnaires, which were included in the database within one week of data collection. All written materials are entered using Epidata software. Specialised data entry staff enter the database within 1 week of the original data collection. A prompt supplement and verify is necessary if data are incomplete or unclear. Participant data will be identified by a unique ID number that will be allocated after the participant gives consent to participate in the study. The ID linking the participant’s identity or personal details will be stored in a password-encrypted file in written and computerised formats. All electronic information will be backed up regularly to avoid loss. Only researchers affiliated with the research will have access to clinic data. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |